Godrej Agrovet reported weak Q2 FY26 results

Godrej Agrovet reported weak Q2 FY26 results with profit after tax down 42% YoY to ₹92.6 crore, though the stock is currently trading higher at around ₹668.90 on September 1, 2026, supported by analyst “buy” ratings and segmental growth in Animal Nutrition and Oil Palm. 📊 Godrej Agrovet – Latest Updates (as of 1 Sept 2026) Q2 FY26 Results (Quarter ended Sept 25, 2026) Total Income: ₹2,567.4 crore (↓1.8% QoQ) Operating Profit: ₹156.3 crore (↓26.2% QoQ) Net Profit (PAT): ₹92.6 crore (↓42.3% QoQ) Operating Margin: 6.1% Diluted EPS: ₹4.81 (↓42.4% QoQ) Stock Performance (1 Sept 2026) Current Price: ₹668.90 (↑8.7% vs last close) 52-Week Range: ₹506.70 – ₹762.95 Debt-to-Equity: 0.49 (higher than industry average) Dividend Yield: 1.81% (above industry average) Analyst Ratings: 4 “Strong Buy”, 1 “Buy”, none “Sell” Strategic Developments Business Transition: Moving from agri-inputs to a high-margin, B2C-focused agri-value chain. Growth Drivers: Animal Nutrition (+12.6% YoY in Q1 FY27) Oil Palm (+28.9% YoY) Dairy (+11.4% YoY, branded products) Challenges: Crop Care segment declined 16.2% YoY due to delayed monsoon. Capex Plan: ₹300–350 crore over 3–4 quarters, targeting 16–18% IRR. Bangladesh JV: Double-digit growth reported. 📈 Key Takeaways for Investors Short-term pressure: Earnings have dropped sharply in Q2 FY26, mainly due to weaker margins and higher expenses. Medium-term outlook: Strong growth in Animal Nutrition, Oil Palm, and Dairy segments may offset Crop Care weakness. Valuation: Current P/E ~24, in line with sector average, but PEG ratio of 1.63 suggests fair valuation. Promoter Holding: 67.7% (stable, indicates confidence). ⚠️ Risks & Watchpoints Monsoon dependency: Crop Care recovery hinges on timely rainfall and product launches. Commodity volatility: Input costs could pressure margins. Debt levels: Debt-to-equity ratio (0.72 consolidated) is higher than peers, requiring monitoring.